Last reviewed · How we verify
NCT04768803: HOGRID
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
trial testing acylated and unacylated ghrelin dosages in Angelman Syndrome in 300 participants. Status unknown.
15 December 2023
Quick facts
| Lead sponsor | University Hospital, Toulouse |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 10 June 2021 |
| Primary completion | 15 December 2023 |
| Estimated completion | 15 December 2023 |
| Sites | 2 locations across France |
Drugs / interventions tested
- acylated and unacylated ghrelin dosages — full drug profile →
Conditions studied
- Angelman Syndrome — all drugs for Angelman Syndrome →
- Smith-Magenis Syndrome — all drugs for Smith-Magenis Syndrome →
- X Fragile Syndrome — all drugs for X Fragile Syndrome →
- Epilepsy — all drugs for Epilepsy →
Sponsor
University Hospital, Toulouse
Who can join
Adults 3 to 50, any sex, with Angelman Syndrome or Smith-Magenis Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A significantly higher proportion of patients with rare diseases (RD) with intellectual disability (ID), present hyperphagia, overweight or obesity, compared to the general population. Prader-Willi syndrome is the only genetic obesity identified to date associated with hyperghrelinemia, while ghrelin levels are lower than in controls in other situations of obesity. The aim of the study is to find out whether the levels of ghrelin, which are abnormally high in PWS throughout life, are also high in these RD when people have hyperphagia and/or overweight.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Unacylated Ghrelin Protects Against Age-Related Loss of Muscle Mass and Contractile Dysfunction in Skeletal Muscle.
Kim H, Ranjit R, Claflin DR, Georgescu C, et al · · 2024 · cited 10× · PMID 39223708 · DOI 10.1111/acel.14323
Verify or expand the search:
- PubMed search for NCT04768803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Angelman Syndrome
Currently open trials in the same condition.
- NCT07181837 — A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome · Phase 1, PHASE2 · recruiting
- NCT06353620 — Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy · recruiting
- NCT06115109 — Angelman Natural History Study - FAST Spain · recruiting
- NCT05293184 — The Global Angelman Syndrome Registry · recruiting
Other University Hospital, Toulouse trials
Trials by the same sponsor.
- NCT07497750 — Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver D · NA · not yet recruiting
- NCT07507240 — The Benefits of a Care Pathway Combining Remote Monitoring and Support From a Nurse After a Change in Anti-epileptic Tre · NA · not yet recruiting
- NCT07524088 — Contamination of Young Children Hair During Acute Cannabis Intoxication · NA · not yet recruiting
- NCT07470580 — Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension · NA · not yet recruiting
- NCT07423988 — Evaluation of Changes in Sleep Efficiency Among PIC DU MIDI Staff Between Nights Spent at Home and Nights Spent in the W · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04768803 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Toulouse
- Last refreshed: 24 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04768803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing